56 results
SC 14D9
SGTX
Sigilon Therapeutics Inc
13 Jul 23
Tender offer solicitation
8:18am
development and commercialization, all research, development and commercialization for any subsequent product candidates, as well as reimbursing Sigilon … for research and development costs required for filing the first IND related to the first developed product candidate that exceed $47.5 million
SC TO-T
EX-99
SGTX
Sigilon Therapeutics Inc
13 Jul 23
Third party tender offer statement
8:01am
for filing the first IND, all subsequent clinical development and commercialization, all research, development and commercialization for any subsequent … product candidates, as well as reimbursing Sigilon for research and development costs required for filing the first IND related to the first developed
8-K
EX-99.1
SGTX
Sigilon Therapeutics Inc
29 Jun 23
Lilly to Acquire Sigilon Therapeutics
7:03am
. “By combining Sigilon’s talent and expertise in cell therapy with the knowledge and skills of Lilly’s research and development teams, we will enhance … the culmination of the important work led by our research and development team to continue advancing SIG-002 at Lilly – the preeminent leader in the treatment
8-K
EX-2.1
SGTX
Sigilon Therapeutics Inc
29 Jun 23
Lilly to Acquire Sigilon Therapeutics
7:03am
Owned Intellectual Property or any other material Company Intellectual Property (or the research or development of any of the foregoing or the funding … for such research or development activities);
(xix) Contract that relates to commercialization, manufacturing, collaboration, co-promotion, discovery
SC TO-C
EX-99.1
78c0bmnu
29 Jun 23
Information about tender offer
6:56am
8-K
EX-99.1
4051peqbbdvfjmeir7
9 May 23
Sigilon Therapeutics Reports First Quarter 2023 Financial Results and Business Highlights
7:37am
8-K
EX-99.1
pp1go60c7u2lcn3p1z
10 Nov 22
Sigilon Therapeutics Reports Third Quarter 2022 Financial Results and Business Highlights
7:37am
8-K
EX-99.2
tfp7wwav9hmfo8odgf
10 Nov 22
Sigilon Therapeutics Reports Third Quarter 2022 Financial Results and Business Highlights
7:37am
8-K
EX-99.1
a2j0qqn
11 Oct 22
Regulation FD Disclosure
8:30am
8-K
EX-99.1
wuwtk8yk6v8ixbx pp6
4 Aug 22
Sigilon Therapeutics Reports Second Quarter 2022 Financial Results and Business Highlights
4:45pm
8-K
EX-99.1
uckcr5cjm4vviopsg
12 May 22
Sigilon Therapeutics Reports First Quarter 2022 Financial Results and Business Highlights
4:16pm
S-3
0fs6y9 mg
14 Apr 22
Shelf registration
4:34pm